Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection

OBJECTIVES: Baloxavir marboxil (formerly S-033188) is a first-in-class, orally available, cap-dependent endonuclease inhibitor licensed in Japan and the USA for the treatment of influenza virus infection. We evaluated the efficacy of delayed oral treatment with baloxavir marboxil in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukao, Keita, Noshi, Takeshi, Yamamoto, Atsuko, Kitano, Mitsutaka, Ando, Yoshinori, Noda, Takahiro, Baba, Kaoru, Matsumoto, Kazumi, Higuchi, Naoko, Ikeda, Minoru, Shishido, Takao, Naito, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376846/
https://www.ncbi.nlm.nih.gov/pubmed/30476172
http://dx.doi.org/10.1093/jac/dky462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376846/
https://www.ncbi.nlm.nih.gov/pubmed/30476172
http://dx.doi.org/10.1093/jac/dky462

Ejemplares similares